The deal marks a significant expansion for The9, a company traditionally focused on the gaming sector and its the9bit digital ecosystem. By diversifying into biotechnology, The9 aims to capitalize on the integration of artificial intelligence within pharmaceutical research. Nanyang Biologics utilizes its proprietary Vecura platform, which draws on a library of over one million natural compounds to identify bioactive candidates often overlooked by conventional synthetic methodologies.

George Lai, CEO of The9, characterized the shareholder vote as a validation of the firm’s long-term investment strategy. While the business combination remains subject to customary closing conditions, the company is preparing to trade under the ticker symbol NYB. This transition represents a shift in The9’s broader corporate portfolio as it balances its core gaming assets with emerging interests in the AI-driven industrial sector.